The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift the clinical hold concerning the nebulizer device used in the Phase 2b trial An independent Data Monitoring Committee (DMC) completed a...Read more
King of Prussia, Pennsylvania--(Newsfile Corp. - November 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced...Read more
BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Phase 2 clinical trial evaluating intranasal foralumab in patients...Read more
Based on MATTERHORN Phase III trial results which showed a 29% reduction in the risk of progression, recurrence or death and a 22% reduction in the risk of death for the IMFINZI regimen vs. chemotherapy alone WILMINGTON, Del. / Nov 26, 2025 / Business Wire / AstraZeneca’s IMFINZI® (durvalumab)...Read more
Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Cohort 8 of the ENDEAVOR study, which is expected to begin before the end of the year The enhanced immunosuppressive regimen is designed to mitigate the risk of acute liver injury (ALI) and acute liver...Read more
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this progressive, relentless disease TOKYO and CAMBRIDGE, Mass., Nov. 25, 2025 /PRNewswire/ --...Read more
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Medical Facilities | 0.74 4.78 | $16.23 |
| BioSyent | 0.49 4.21 | $12.12 |
| Cipher Pharmaceuticals | 0.42 2.84 | $15.20 |
| VitalHub | 0.14 1.52 | $9.33 |
| Eupraxia Pharmaceuticals | 0.08 0.92 | $8.80 |
| WELL Health Technologies | 0.07 1.84 | $3.88 |
| Arch Biopartners | 0.05 4.85 | $1.08 |
| Covalon Technologies | 0.04 2.13 | $1.92 |
| NetraMark | 0.03 2.68 | $1.15 |
| Knight Therapeutics | 0.02 0.33 | $6.07 |
| Sernova Biotherapeutics | 0.02 13.79 | $0.17 |
| NeuPath Health | 0.02 5.13 | $0.41 |
| Medicenna Therapeutics | 0.01 0.67 | $1.51 |
| Hemostemix | 0.01 12.50 | $0.09 |
| Satellos Bioscience | 0.01 1.45 | $0.70 |
| Appili Therapeutics | 0.005 25.00 | $0.03 |
| Microbix Biosystems | 0.005 2.08 | $0.25 |
| Premier Health | 0.005 25.00 | $0.03 |
| Company | Volume | Last Trade |
|---|---|---|
| WELL Health Technologies | 763,617 | $3.88 |
| Voyageur Pharmaceuticals | 688,094 | $0.15 |
| Theralase Technologies | 473,800 | $0.16 |
| HEALWELL AI | 455,905 | $0.92 |
| Sernova Biotherapeutics | 289,301 | $0.17 |
| NeuPath Health | 231,550 | $0.41 |
| LevelJump Healthcare | 185,000 | $0.05 |
| Hemostemix | 175,010 | $0.09 |
| Therma Bright | 151,933 | $0.05 |
| BioNxt Solutions | 137,771 | $0.67 |
| Nervgen Pharma | 111,786 | $5.31 |
| Medexus Pharmaceuticals | 96,108 | $2.67 |
| Ocumetics Technology | 88,065 | $0.67 |
| Perimeter Medical Imaging AI | 80,824 | $0.18 |
| Izotropic | 61,286 | $0.29 |
| Premier Health | 50,000 | $0.03 |
| VitalHub | 35,292 | $9.33 |
| NetraMark | 33,800 | $1.15 |
| Medical Facilities | 28,153 | $16.23 |
Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
